46.70
-0.96 (-2.01%)
| Previous Close | 47.66 |
| Open | 47.47 |
| Volume | 2,676,081 |
| Avg. Volume (3M) | 2,351,911 |
| Market Cap | 4,033,184,768 |
| Price / Earnings (Forward) | 23.36 |
| Price / Sales | 108.40 |
| Price / Book | 2.10 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Operating Margin (TTM) | -17,158.84% |
| Diluted EPS (TTM) | -4.49 |
| Quarterly Revenue Growth (YOY) | 71.60% |
| Total Debt/Equity (MRQ) | 11.99% |
| Current Ratio (MRQ) | 15.64 |
| Operating Cash Flow (TTM) | -306.47 M |
| Levered Free Cash Flow (TTM) | -193.24 M |
| Return on Assets (TTM) | -12.88% |
| Return on Equity (TTM) | -19.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | CRISPR Therapeutics AG | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 1.76% |
| % Held by Institutions | 80.46% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Capital International Investors | 31 Mar 2025 | 6,073,118 |
| Orbis Allan Gray Ltd | 31 Mar 2025 | 1,562,932 |
| Ecor1 Capital, Llc | 31 Mar 2025 | 1,389,276 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 86.00 (JMP Securities, 84.15%) | Buy |
| Median | 73.00 (56.32%) | |
| Low | 42.00 (Barclays, -10.06%) | Hold |
| Average | 67.17 (43.83%) | |
| Total | 4 Buy, 2 Hold | |
| Avg. Price @ Call | 40.23 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 26 Jun 2025 | 82.00 (75.59%) | Buy | 46.70 |
| 07 May 2025 | 82.00 (75.59%) | Buy | 34.25 | |
| Needham | 26 Jun 2025 | 81.00 (73.45%) | Buy | 46.70 |
| 20 May 2025 | 81.00 (73.45%) | Buy | 39.25 | |
| JMP Securities | 21 May 2025 | 86.00 (84.15%) | Buy | 36.99 |
| HC Wainwright & Co. | 20 May 2025 | 65.00 (39.19%) | Buy | 39.25 |
| Barclays | 09 May 2025 | 42.00 (-10.06%) | Hold | 35.62 |
| Goldman Sachs | 08 May 2025 | 47.00 (0.64%) | Hold | 36.14 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Jun 2025 | Announcement | CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline |
| 29 May 2025 | Announcement | CRISPR Therapeutics to Participate in Upcoming Investor Conferences |
| 19 May 2025 | Announcement | CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies |
| 06 May 2025 | Announcement | CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3 |
| 03 Apr 2025 | Announcement | CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference |
| 02 Apr 2025 | Announcement | Stem Cell Innovators: 4 Companies Advancing Regenerative Medicine |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |